Trial Profile
A randomised, double blind study to assess the effect of varying doses of incobotulinumtoxinA on the safety, efficacy, and duration of treatment effect for Glabellar Frown Lines
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 May 2018
Price :
$35
*
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Glabellar lines
- Focus Adverse reactions; Therapeutic Use
- 10 May 2018 New trial record